Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 15/20 | 0.76 |
| ▸ | WDR77 | Q9BQA1 | 14/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18026117 | 1.00 | PRMT5 (0.76) | PRMT5WDR77ADORA2AADORA2BDNMT1 | |
| SCHEMBL18039043 | 0.86 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL21413928 | 0.86 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL18009839 | 0.86 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL18026170 | 0.82 | PRMT5 (0.64) | PRMT5WDR77 | |
| SCHEMBL18026021 | 0.80 | ADORA2B (0.58) | PRMT5WDR77ADORA2AADORA2BDNMT1 | |
| SCHEMBL18026087 | 0.80 | ADORA2B (0.58) | PRMT5WDR77ADORA2AADORA2BDNMT1 | |
| SCHEMBL18026026 | 0.80 | ADORA2B (0.58) | PRMT5WDR77ADORA2AADORA2BDNMT1 | |
| SCHEMBL24625951 | 0.78 | PRMT5 (0.84) | PRMT5WDR77 | |
| SCHEMBL24478704 | 0.78 | PRMT5 (0.84) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | PRMT5 1552/4885WDR77 2124/4885ADORA2A 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.